North America

As Democratic leaders try to establish a politically feasible path forward for the $3.5 trillion budget reconciliation bill, they appear to be caving in to the demands of a small, but influential group of House and Senate centrists.

Despite the feverish negotiations and the stakes involved, more than half of Americans are not closely watching the debate in Congress, according to the poll.

The proposals in flux range from tinkering with tax credits to far-reaching changes in federal payments systems.

This initiative involves collaborating with decision makers and developing policies to reduce prescription drug spending without stifling innovation in the pharmaceutical industry.

"Opposing these policies doesn't make you a moderate," said Warren Gunnels. "It doesn't make you a centrist. It makes you an extremist."

In each instance, the companies — the Sandoz unit at Novartis, Taro Pharmaceuticals and Apotex — admitted to working with rivals to set prices and supplies, and allocate customers for different medicines between 2013 and 2015.

Antiviral drugs that keep some coronavirus patients out of the hospital are badly needed, and investors know it.

A new poll found that 56% of voters support giving Medicare the power to negotiate for lower drug prices for certain products, but only 50% want it to be included in a major infrastructure package.

Polls show that 65% of voters would oppose the legislation to lower drug prices if it reduced the supply of new drugs.

Attorney General Leslie Rutledge announced today a $15.2 million settlement with Centene Corporation and three subsidiaries for overcharging the state Medicaid program for medication.

Undisclosed in the heart-wrenching commercials: The Partnership to Fight Chronic Disease has extensive ties to the lobby for major pharmaceutical companies, the Pharmaceutical Research and Manufacturers of America, or PhRMA.

For 17 of the 20 top-selling drugs in the world in 2020, pharmaceutical companies made more in revenue from U.S. sales than they did in every other country put together.

It’s a sign the drug industry is bending a potential compromise in manufacturers’ favor after spending more than $171 million lobbying in the first half of this year.

This lecture will describe the US FDA approval of aducanumab (Aduhelm) for Alzheimer disease and the implications the approval has had across the US health care system.

While the votes were not unanimous, they passed the committee by a big margin. A fourth measure is set to be considered on Thursday.